We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Screening Program Prevents Transfusion-Transmitted Babesiosis

By LabMedica International staff writers
Posted on 20 Aug 2012
A laboratory-based blood donor-screening program for Babesia microti has been developed and implemented to reduce transfusion-transmitted babesiosis (TTB). More...


Selective B. microti donor screening was performed using real-time polymerase chain reaction (PCR) and indirect immunofluorescence assay (IFA) to reduce the incidence of TTB in neonates and pediatric sickle cell and thalassemia patients.

A team of scientists collaborating with the Rhode Island Blood Center (Providence, RI, USA) screened 2,113 units of blood from 1,783 eligible donors for the presence of B. microti between July 8, 2010, and June 30, 2011. B. microti antibody testing was performed at Imugen, Inc. (Norwood, MA, USA) using an IFA method with additional modifications to improve sensitivity and specificity and to facilitate future high-throughput screening. PCR was carried out employing primers and probes targeting the B. microti 18S ribosomal ribonucleic acid (RNA) gene and was also performed at Imugen, Inc., using a highly sensitive and specific real-time fast PCR method approved by the US Food and Drug Administration (FDA; Silver Springs, MD, USA).

There were 2,113 units tested with 2,086 negative results, 26 positive IFA results (1.23%), and one indeterminate PCR result (0.05%). No reported case of TTB occurred with any B. microti–screened unit transfused to the targeted patients (0/787 units) or to any patient who received the screened units (0/2,086 units). Before screening, there were seven cases of TTB in neonates, sickle cell, and thalassemia patients from 6,500 unscreened units (one case/929 units) and 24 cases in the total transfused population from 496,545 units distributed (one case/20,686 units).

The authors concluded that the problem of donor loss due to laboratory screening would be outweighed by the benefit of increased protection such screening provides. After three neonatal TTB cases occurred from one infected donor in 2006, the hospital began transfusing one red blood cell unit per patient with up to 10 aliquots per unit. The hospital with screening could safely use one unit for many neonates. The prescreening TTB incidence data of 1 in 995 aliquots compared to the postscreening TTB incidence of 0 in 545 aliquots are promising. Therefore, donor testing mitigated TTB in a highly vulnerable recipient population.

Babesia microti, the most common cause of human babesiosis, is also the most frequently reported transfusion-transmitted microbial pathogen in the United States with 159 cases of transfusion-associated infection reported during 1979 to 2009, involving 19 states. Rhode Island is highly endemic for babesiosis with rates of reported babesiosis exceeding 90 cases per 100,000 in 2008. The study was published in the July 2012 edition of the journal Transfusion.

Related Links:
Rhode Island Blood Center
Imugen, Inc.
US Food and Drug Administration



New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Serological Pipet Controller
PIPETBOY GENIUS
New
Candida Glabrata Test
ELIchrom Glabrata
New
Automated Biochemical Analyzer
iBC 900
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.